When Should Progression Lead to Treatment Changes? - 2022 Program: Targeted Therapies Forum

EGFR Mutated NSCLC Disease Progression on Osimertinib - 2022 Program: Targeted Therapies ForumПодробнее

HER2+ NSCLC: When to Introduce Targeted Therapies - 2022 Program: Targeted Therapies ForumПодробнее

Treatment of HER2+ NSCLC - 2022 Program: Targeted Therapies ForumПодробнее

Advice for Newly Diagnosed Patients - 2022 Program: Targeted Therapies ForumПодробнее

Disease Progression on Lorlatinib or Osimertinib - 2022 Program: Targeted Therapies ForumПодробнее

Progression on Sotorasib with KRAS+ NSCLC - 2022 Program: Targeted Therapies ForumПодробнее

Evolving Treatment for NSCLC: Targeted Therapies - 2022 Program: Targeted Therapies ForumПодробнее

What is Oligoprogression? - 2022 Program:Targeted Therapies ForumПодробнее

Treatment of Oligoprogression - 2022 Program: Targeted Therapies ForumПодробнее

Side Effects: Treating Mouth Sores & Finding Clinical Trials -2022 Program: Targeted Therapies ForumПодробнее

Treatment for NTRK+ NSCLC: Larotrectinib & Entrectinib - 2022 Program: Targeted Therapies ForumПодробнее

RET+ NSCLC Treatment Options - 2022 Program: Targeted Therapies ForumПодробнее

Oligoprogression in EGFR Mutant NSCLC - 2022 Program:Targeted Therapies ForumПодробнее

ALK+ NSCLC Treatment Options - 2022 Program: Targeted Therapies ForumПодробнее

Changes in the Field of Metastatic NSCLC - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Identifying Oligoprogression in a Patient - 2022 Program: Targeted Therapies ForumПодробнее

Lesion After Reduced Alectinib: Add Chemo and Pemetrexed? - 2022 Program: Targeted Therapies ForumПодробнее

Treatments for RET+ NSCLC: Selpercatinib vs. Pralsetinib - 2022 Program: Targeted Therapies ForumПодробнее